Weight Loss Via Intelligent Guidance in Patients With Coronary Heart Disease and Obesity: a Randomized Clinical Trial

Summary

Coronary Heart Disease (CHD) is an ischemic heart disease caused by coronary atherosclerosis, and it is the leading cause of death from cardiovascular diseases worldwide. Weight loss in obese patients can significantly improve metabolic indicators such as dyslipidemia and insulin resistance; therefore, weight loss may become a target for improving the prognosis of obese patients with coronary heart disease. This study is a multicenter, randomized controlled clinical trial aimed at evaluating the effect of software-based healthy weight loss guidance (personalized diet + exercise intervention) in obese patients with coronary heart disease. It is expected that 136 patients will be enrolled in hospitals including Guangdong Provincial People's Hospital, with a total study duration of 1 year.

Conditions

• CHD
• Overweight or Obese

Interventions

BEHAVIORAL

dietary regulation and structured exercise training

This study implements a personalized intervention combining dietary regulation, exercise training, safety protocols, and adherence assessment. Dietary intervention: Target energy intake = basal energy expenditure×1.3-500kcal; basal energy expenditure is estimated via gender-specific Harris-Benedict formula (0.9 correction), ideal weight by height and BMI 24.9. Macronutrient ratios are selected based on comorbidities and baseline indicators; software generates personalized meal plans, with participants uploading daily food photos for calorie/nutrient analysis and reports. Exercise intervention: Standardized guidance and progressive prescriptions are provided. Aerobic intensity (CPET-determined anaerobic threshold heart rate±10) involves ultra-slow jogging/brisk walking (150-180 steps/min, RPE 10-12), 30-40min core training +10min warm-up/cool-down, ≥5 times/week. Elastic band resistance training (≥3 times/week) uses video guidance.

Sponsors & Collaborators

• Yuebei People's Hospital

  collaborator OTHER

• Guangzhou Red Cross Hospital

  collaborator OTHER

• Zhongshan Hospital Of Traditional Chinese Medicine

  collaborator OTHER

• Shenzhen Nanshan Institute of Chronic Disease Control

  collaborator UNKNOWN

• Dongguan Binhaiwan Central Hospital

  collaborator UNKNOWN

• The Eighth People's Hospital of Nanning

  collaborator UNKNOWN

• People's Hospital of Xinjiang Uygur Autonomous Region

  collaborator OTHER

• Nanyang Central Hospital

  collaborator OTHER

• The First People's Hospital of Yunnan

  collaborator OTHER

• The First People's Hospital of Nanning

  collaborator UNKNOWN

• Guangdong Provincial People's Hospital

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2026-04-18

Primary Completion

2028-07-31

Completion

2028-12-31

Countries

• China

Study Locations